Biotherapeutic for the Treatment of Atopic Dermatitis in Client-Owned Dogs Current Status: Open and enrolling
Principal Investigator: Sheila M. F. Torres, DVM, MS, PhD, DACVD
Contact:
Sara Pracht, CVT - phone: 612-626-3574, e-mail prach011@umn.edu
Dr. Torres - phone: 612-624-3746, e-mail torre009@umn.edu
We are now enrolling dogs with year-round allergies (atopic dermatitis (AD)) for a study to evaluate the safety and efficacy of an investigational veterinary product compared to placebo in controlling the clinical signs associated with this condition. This new product is injectable and will be given in our clinic. This is a 56-day study, with one injection on Day 0, a total six visits to the VMC which are all covered by the study, plus a $400 incentive for the owner's time and travel. To be in the study, dogs must: - be diagnosed with year-round allergies
- be a year old or more
- have undergone a food trial to eliminate food allergies
- be flea-free and on flea preventative (we will supply)
- not have any infections nor on long term antibiotic therapy
Before starting the clinical trial, dogs will be withdrawn from glucocorticoids, antihistamines, cyclosporine A, or other anti-inflammatory or immunosuppressive drugs. Some topical treatments may still be allowed, if they were in use for at least 6 weeks prior to enrollment, and if their use is continued without changing. We will go over this with all prospective clients. This study uses an online system for recording information at home by the owner. It will be important that the same owner is available to consistently evaluate the dog's itchiness. For more information, please contact Sara Pracht or Dr. Torres. | 
Dr. Sheila Torres and patient |
